Immunological Profile of Solid Tumors Sample

Study Overview
=================
Brief Summary
-----------------
It has become clear in the recent year that the nature of the immune cells infiltrate within a tumor was essential in the control of the tumor growth. This so-called immune contexture does vary between cancer types and in response to treatments. In this context, this trial is a non-interventional, mono-centric in patients with solid tumors. Samples in paraffin-embedded material block of biopsies or surgical pieces (either primitive tumor or metastases) will be analysed. For each sample, clinically relevant data associated with treated cancer and needed for characterization of tumor microenvironment will be documented. This trial is, through accessing to well documented selected archival tumor materials, to validate selected biomarker for early phase trial.

Official Title
-----------------
Study of the Immunological Profile of Archival Formalin-fixed Paraffin-embedded Solid Tumors Sample

Conditions
-----------------
Solid Cancer

Intervention / Treatment
-----------------
* Other: immunohistochemistry assay


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sample must have had a valid written informed consent for available archival tumor samples for scientific purposes. Sample from patients with histologically documented cancer in target population. Exclusion Criteria: Samples from subject unwilling to give their informed consent; Unusable sample or biologically deteriorated.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung cancer<br> | Other: immunohistochemistry assay<br>* biomarkers expression<br>|
| Central Nervous System Cancers<br> | Other: immunohistochemistry assay<br>* biomarkers expression<br>|
| Head and Neck and upper aero-digestive tract cancers<br> | Other: immunohistochemistry assay<br>* biomarkers expression<br>|
| Skin cancers<br> | Other: immunohistochemistry assay<br>* biomarkers expression<br>|
| Sarcomas<br> | Other: immunohistochemistry assay<br>* biomarkers expression<br>|
| Urothelial cancer<br> | Other: immunohistochemistry assay<br>* biomarkers expression<br>|
| Hepatocarcinoma<br> | Other: immunohistochemistry assay<br>* biomarkers expression<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immunohistochemistry scores | The immunohistochemistry scores is evaluated with the score of the percentage of stained cells. Scale of the score of the percentage of stained cells, From 0 to 4, 0 : no stained cell (absence) : < 10 % stained cell (minimal) : 10 to 50 % (mild) : 51 to 79 % (moderate) : = or > 80 % (marked) | 24 months | 
| Immunohistochemistry scores | The immunohistochemistry scores is evaluated with the score of the staining intensity. Staining Intensity: from 0 to 3 0 : no staining (absence) : low staining : middle staining : high staining | 24 months |